We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cidara Therapeutics Inc (CDTX) USD0.0001

Sell:$10.45 Buy:$13.38 Change: $0.85 (6.32%)
Market closed |  Prices as at close on 17 June 2024 | Switch to live prices |
Change: $0.85 (6.32%)
Market closed |  Prices as at close on 17 June 2024 | Switch to live prices |
Change: $0.85 (6.32%)
Market closed |  Prices as at close on 17 June 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Contact details

6310 Nancy Ridge Dr Ste 101
United States
+1 (858) 7526170

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$61.31 million
Shares in issue:
4.56 million
United States
US dollar

Key personnel

  • Jeffrey Stein
    President, Chief Executive Officer, Director
  • Preetam Shah
    Chief Financial Officer, Chief Business Officer
  • Shane Ward
    Chief Operating Officer, Company Secretary
  • Leslie Tari
    Chief Scientific Officer
  • Taylor Sandison
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.